Zhejiang Hisun Pharmaceutical Co., Ltd. Class ASSE: 600267

"Zhejiang Hisun Pharmaceutical Co., Ltd."Announcement on the Obtainment of CEP Certificate for Epirubicin Hydrochloride Active Pharmaceutical Ingredient

Aug 25, 2026 · Issued by Zhejiang Hisun Pharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange

Announcement on the Obtainment of CEP Certificate for Epirubicin Hydrochloride Active Pharmaceutical Ingredient

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Earlier from Zhejiang Hisun Pharmaceutical Co., Ltd. Class A

"Zhejiang Hisun Pharmaceutical Co., Ltd."Announcement on Release of Overdue Guarantee for an Investee SubsidiaryAug 21
"Zhejiang Hisun Pharmaceutical Co., Ltd."Announcement on the Company's Proposed Selection in the National Centralized Drug ProcurementAug 4
"Zhejiang Hisun Pharmaceutical Co., Ltd."Announcement on the U.S. FDA Approval of Fludarabine Phosphate Injection of the Wholly-owned SubsidiaryJul 25
"Zhejiang Hisun Pharmaceutical Co., Ltd."Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026Jul 21

All Zhejiang Hisun Pharmaceutical Co., Ltd. Class A news releases